Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK4AML allogeneic NK cell infusion plus subcutaneous IL-2 in AML/MDS
2024-515357-16-00Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of RNK001 and aldesleukin in acute myeloid leukemia (AML), myelodysplastic syndrome with excess blasts (MDS-EB) and myelodysplastic syndrome (MDS), sponsored by Radboud University Medical Center. Primary endpoints: Phase I safety and dose-limiting toxicity and Phase IIa clinical response by day +28. Started Jan 2025; status: completed.
02
Drugs
RNK001aldesleukin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome with excess blasts (MDS-EB)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2024-515357-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515357-16-00.